



NDA 021292/S-010

**SUPPLEMENT APPROVAL**

Provell Pharmaceuticals, LLC  
c/o ICON Clinical Research LLC  
Attention: Amy B. Kneifel, RAC  
Director, Regulatory Affairs  
4130 Parklake Avenue, Suite 400  
Raleigh, NC 27612

Dear Ms. Kneifel:

Please refer to your Supplemental New Drug Application (sNDA) dated and received November 5, 2021, and your amendment, submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Euthyrox (levothyroxine sodium) tablets.

This Prior Approval supplemental new drug application provides for the addition of 90-count blister presentation.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling and with minor editorial revisions listed below and reflected in the enclosed labeling.

The revision date listed at the end of the Highlights of Prescribing Information and at the end of the package insert has been updated to "04/2022"

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to, except with the revisions listed, the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions listed above approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND CONTAINER LABELS**

Submit final printed carton and container labels that are identical to enclosed carton and container labels and carton and container labels submitted on March 24, 2022 and box container labels submitted on November 5, 2021, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 021292/S-010.**” Approval of this submission by FDA is not required before the labeling is used.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Christopher LaFleur, Regulatory Business Process Manager, at (240) 402 - 4724.

Sincerely,

*{See appended electronic signature page}*

Ramesh Raghavachari, Ph.D.  
Chief, Branch 1  
Division of Post-Marketing Activities I  
Office of Lifecycle Drug Products  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosures:

Content of Labeling  
Carton and Container Labeling

U.S. Food & Drug Administration  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)



Ramesh  
Raghavachari

Digitally signed by Ramesh Raghavachari  
Date: 4/27/2022 04:59:07PM  
GUID: 502d0913000029f375128b0de8c50020